A pharmaceutical startup, Ortholevo Inc is anchored in a demonstrated track record by the firm's principals of having individually achieved in use-condition of various teatments for fibrotic diseases of joints, muscles, lungs, and connective tissues. The firm's offered technology is indicated as having safely and non-surgically treated the fibrosis from neuromuscular diseases, post-COVID-19 pulmonary fibrosis, musculoskeletal and congenital conditions, cosmetic ailments, inflammatory diseases, and many other pathologies. Anchored in proof-of-concept animal studies, the effort is now to complete additional preclinical studies in preparation for a first-in-human clinical trial.
